Fumiya Ebihara

Agreement between one-point and two-point sampling for vancomycin AUC estimation at follow-up TDM using the Yasuhara population pharmacokinetic model.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: July 07, 2026

Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: January 14, 2026

Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study.

Journal: The Journal of antimicrobial chemotherapy

Published: October 04, 2025

Optimization of cefepime dosage regimens for Pseudomonas aeruginosa infections in Japanese patients based on a pharmacokinetic/ pharmacodynamic analysis considering efficacy and safety: Is a 6 g daily dose and continuous infusion necessary?

Journal: Global health & medicine

Published: September 11, 2025

Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: July 24, 2025

Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: July 08, 2025

Preclinical Study of Pharmacokinetic/Pharmacodynamic Analysis of Tebipenem Using Monte Carlo Simulation for Extended-Spectrum β-Lactamase-Producing Bacterial Urinary Tract Infections in Japanese Patients According to Renal Function.

Journal: Antibiotics (Basel, Switzerland)

Published: June 11, 2025

Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.

Journal: Journal of pharmaceutical health care and sciences

Published: April 01, 2025

External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: February 21, 2025

Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.

Journal: The Journal of pharmacy and pharmacology

Published: November 20, 2024

Agreement between one-point and two-point sampling for vancomycin AUC estimation at follow-up TDM using the Yasuhara population pharmacokinetic model.

Agreement between one-point and two-point sampling for vancomycin AUC estimation at follow-up TDM using the Yasuhara population pharmacokinetic model.

Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling.

Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling.

Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study.

Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study.

Optimization of cefepime dosage regimens for Pseudomonas aeruginosa infections in Japanese patients based on a pharmacokinetic/ pharmacodynamic analysis considering efficacy and safety: Is a 6 g daily dose and continuous infusion necessary?

Optimization of cefepime dosage regimens for Pseudomonas aeruginosa infections in Japanese patients based on a pharmacokinetic/ pharmacodynamic analysis considering efficacy and safety: Is a 6 g daily dose and continuous infusion necessary?

Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring.

Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring.

Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients.

Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients.

Preclinical Study of Pharmacokinetic/Pharmacodynamic Analysis of Tebipenem Using Monte Carlo Simulation for Extended-Spectrum β-Lactamase-Producing Bacterial Urinary Tract Infections in Japanese Patients According to Renal Function.

Preclinical Study of Pharmacokinetic/Pharmacodynamic Analysis of Tebipenem Using Monte Carlo Simulation for Extended-Spectrum β-Lactamase-Producing Bacterial Urinary Tract Infections in Japanese Patients According to Renal Function.

Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.

Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.

External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study.

External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study.

Reply to Mitsuboshi, "Enhancing result reliability by addressing potential confounding factors".

Reply to Mitsuboshi, "Enhancing result reliability by addressing potential confounding factors".

Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.

Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.

Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.

Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.